Marc A. Began
Net Worth
Last updated:
What is Marc A. Began net worth?
The estimated net worth of Mr. Marc A. Began is at least $8,161,336 as of 4 Nov 2022. He owns shares worth $5,252,361 as insider, has earned $875,395 from insider trading and has received compensation worth at least $2,033,580 in Abiomed, Inc. and Abiomed, Inc..
What is the salary of Marc A. Began?
Mr. Marc A. Began salary is $677,860 per year as Vice President, Gen. Counsel & Sec. in Abiomed, Inc..
How old is Marc A. Began?
Mr. Marc A. Began is 58 years old, born in 1967.
What stocks does Marc A. Began currently own?
As insider, Mr. Marc A. Began owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Abiomed, Inc. (ABMD) | Vice President, Gen. Counsel & Sec. | 13,785 | $381.02 | $5,252,361 |
What does Abiomed, Inc. do?
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Marc A. Began insider trading
Abiomed, Inc.
Mr. Marc A. Began has made 2 insider trades in 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of ABMD stock worth $747,420 on 4 Nov 2022.
The largest trade he's ever made was exercising 2,000 units of ABMD stock on 4 Nov 2022. As of 4 Nov 2022 he still owns at least 13,785 units of ABMD stock.
Abiomed key executives
Abiomed, Inc. executives and other stock owners filed with the SEC:
- Dr. David M. Weber (64) Senior Vice President & Chief Operating Officer
- Mr. Andrew J. Greenfield (52) Vice President & Chief Commercial Officer
- Mr. Marc A. Began (58) Vice President, Gen. Counsel & Sec.
- Mr. Michael R. Minogue (58) Chairman, Chief Executive Officer & Pres
- Mr. Todd A. Trapp (54) Chief Financial Officer & Vice President